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Risk assessmentHematopoietic stem cell transplantation (HSCT) is a lifesaving expensive medical procedure. Hence, more trans-
plants are performed in more afﬂuent countries. The impact of economic factors on patient outcome is less de-
ﬁned. We analyzed retrospectively a deﬁned cohort of 102,549 patients treated with an allogeneic (N =
37,542; 37%) or autologous (N = 65,007; 63%) HSCT. They were transplanted by one of 404 HSCT centers in
25 European countries between 1999 and 2006.We searched for associations between center-speciﬁcmicroeco-
nomic or country-speciﬁc macroeconomic factors and outcome. Center patient-volume and center program-
duration were signiﬁcantly and systematically associated with improved survival after allogeneic HSCT (HR
0·87; 0·84–0·91 per 10 patients; p b 0·0001; HR 0·90;0·85–0·90 per 10 years; p b 0·001) and autologous
HSCT (HR 0·91;0·87–0·96 per 10 patients; p b 0·001; HR 0·93;0·87–0·99 per 10 years; p=0·02). The product
of Health Care Expenditures byGross National Income/capitawas signiﬁcantly associated inmultivariate analysis
with all endpoints (R2 = 18%; for relapse free survival) after allogeneic HSCT. Data indicate that country- and
center-speciﬁc economic factors are associatedwith distinct, signiﬁcant, systematic, and clinically relevant effects
on survival after HSCT. They impact on center expertise in long-term disease and complicationmanagement. It is
likely that these ﬁndings apply to other forms of complex treatments.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).ﬁce, University Hospital Basel,
l).
. This is an open access article under1. Introduction
The close relationship between the economy of individual countries
and the extent of their medical activities has long been accepted as real-
ity but has become a topic of research only in the last decade (Waitzkinthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Table 1
Patient characteristics
Demographics of 102,549 HSCT (allogeneic 37,542; 37% and autologous 65,007; 63%)
between 1999 and 2006 in Europe.
Allogeneic HSCT Autologous HSCT Total
N centers 299 401 404
JACIE⁎ accredited 119 133 135
2102 A. Gratwohl et al. / EBioMedicine 2 (2015) 2101–21092003). The relevance ofmacroeconomics in health provision has recent-
ly been highlighted by the World Health Organization (WHO), with
more solid organ and hematopoietic stem cell transplants (HSCT) per-
formed in more afﬂuent countries (White et al. 2014; Gratwohl et al.
2015). Allogeneic HSCT represents one role model of a low volume,
high cost, but lifesaving medical procedure (Copelan 2006; Majhail
et al. 2013; Khera et al. 2012). There is a strong association of country-
speciﬁc economic factors with its use. Extensive studies have indicated
signiﬁcant correlations between transplant rates, e.g. thenumber of trans-
plants compared to the number of inhabitants, and macroeconomic indi-
ces such as Gross National Income/capita (GNI/cap) or the availability of
an unrelated donor registry. For a functioning national transplant net-
work, a countrymust have aminimum size and aminimum of resources,
teams require a minimum of support, donors must be available and
patients have to have access to the transplant (Gratwohl et al. 2015;
Gratwohl et al. 2010a; Gratwohl et al. 2010b).
It is intuitive that country-speciﬁc macroeconomic factors could
have an impact on outcome as well. The vast numbers of well recog-
nized patient-, disease-, donor- and transplant technique associated
risk factors hamper simple comparisons (Copelan 2006; Giebel et al.
2010; Gratwohl et al. 2009). There is as well a potential independent
role of center-speciﬁc microeconomic factors at the level of the individ-
ual team. Complex medical procedures require the close cooperation of
multiple persons and institutions, training, competency and experience;
in short, team expertise. The role of “minimal center size” or “patient/
hospital volume” has been discussed for many years, with conﬂicting
data (Loberiza et al. 2005; Gratwohl et al. 1989; Frassoni et al. 2000;
Matsuo et al. 2000; Giebel et al. 2013; Klingebiel et al. 2010; Horowitz
et al. 1992; Taylor et al. 2013).The topic of “center experience” is not re-
stricted to HSCT but a matter of debate in many ﬁelds of medicine. Data
suggest that minimum numbers of speciﬁc practice are required to per-
form complex medical procedures safely; again, results have been con-
ﬂicting (Hunsicker et al. 1993; Ozhathil et al. 2011; Guba 2014;
Birkmeyer et al. 2003; Lüchtenborg et al. 2013). Hence, relatively arbi-
trary thresholds have been set in accreditation standards (Jones et al.
2006; http://www.jacie.org/standards/6th-edition-2015 n.d.). How-
ever, patient interest groups, health policymakers, competent authorities
and other stakeholders are increasingly asking for objective measures of
patient safety and outcome. They expect transparency and fair systems
of comparisons between centers (Horowitz et al. 1992; Logan et al. 2008).
We previously identiﬁed JACIE accreditation as a center-speciﬁc
factor after allogeneic HSCT and found indications for an effect of patient
volume (Gratwohl et al. 2014). We used this well-deﬁned large cohort of
patients to investigate the multifaceted relationship between potential
center- and country-speciﬁc economic factors and long-term outcome
after the less complex autologous or the more complex allogeneic HSCT.JACIE⁎ not accredited 180 268 269
N Patients 37,542 65,007 102,549
Male % 21,797 (58.2%) 38,089 (58.7%) 59,886 (58.5%)
Age
Median (years) 39·2 53·4 49·1
b20 years 7326 (20%) 2240 (3%) 9566 (9%)
20–40 years 12,055 (32%) 11,800 (18%) 23,855 (23%)
40–60 years 15,563 (41%) 33,973 (52%) 49,536 (48%)
N60 years 2598 (7%) 16,994 (26%) 19,592 (19%)
Disease
Acute leukemia 21,991 (59%) 6361 (10%) 28,352 (27%)
Chronic leukemia 7486 (20%) 1556 (2%) 9042 (9%)
MDS/MPS 3864 (10%) 232 (b1%) 4096 (4%)
Lymphoma 3307 (9%) 32,358 (50%) 35,665(35%)
PCD 894 (2%) 24,500 (38%) 25,394 (25%)
Year Transplant
1999–2002 17,589 (47%) 29,368 (45%) 46,957 (46%)
2003–2006 19,953 (53%) 35,639 (55%) 55,592 (54%)
0–I 5444(15%) 3755 (6%) 9199 (9%)
II–III 16,680 (44%) 35,623 (55%) 52,303 (51%)
IV–V 13,352 (36%) 25,629 (39%) 38,981 (38%)
VI–VII 2066 (5%) 0 2066(2%)
⁎ JACIE = Joint Accreditation Committee of the International Society for Cellular Therapy
and the European Society for Blood and Marrow Transplantation (www.jacie.org).2. Methods
2.1. Study design
This retrospective observational analysis was based on a previously
published cohort. It consists of patients transplanted between January
1st 1999 and December 31st 2006 and reported by 404 teams (see
appendix) to the European Society for Blood and Marrow Transplanta-
tion (EBMT) database (www.ebmt.org) (Gratwohl et al. 2014). The
analysiswas initiated on January 1st 2013;when all analyseswere com-
pleted, patient's survival data were updated as of January 1st, 2015. Last
follow-up time was used as endpoint. Endpoints in all analyses were
overall survival, relapse, non-relapsemortality and relapse free survival.
They served as indicators for team expertise in complication manage-
ment (non-relapse mortality), and as indicators for team expertise in
disease management (relapse incidence). Relapse incidence and non-
relapsemortalitywere taken as competing risks. All datawere censored
at 8 years post HSCT to provide for a homogeneous observation period.All EBMT teams are required to obtain patients' consent and to have
internal review board approval for their transplant programs and for
data transfer to EBMT. The present study was released by the Ethics
Committee Nordwest- and Zentralschweiz (www.eknz.ch).
2.2. Patient population
The cohort was restricted to 102,549 patients, 59%males, with a ﬁrst
allogeneic (N=37,542; 37%) or autologousHSCT (N=65,007; 63%) for
an acquired hematological malignancy from 1999 to 2006 (Table 1).
This corresponds to 93% of all patients transplanted during this time
frame by the participating teams with these indications (see appendix).
The cohort was heterogeneous; there was an increase in acute and a
decrease in chronic myeloid leukemia and an increase in EBMT risk
score over time (Gratwohl et al. 2009). AllogeneicHSCTwas preferentially
used for acute leukemias (N=21,991; 78% allogeneic), chronic leukemias
(N = 7486; 83% allogeneic) and myelodysplastic/myeloproliferative dis-
orders (N = 3864; 94% allogeneic); autologous HSCT was preferentially
used for lymphoma (N= 32,358; 91% autologous) and plasma cell disor-
ders (N = 24,500; 95% autologous) (Table 1; Fig. 1). There were sig-
niﬁcant differences between centers regarding program duration
(Fig. 1a, b; supplementary Fig. 1a), and patient volume (Fig. 1c; sup-
plementary Fig. 1b), and between accredited and non accredited
centers (Gratwohl et al. 2014).
2.3. Deﬁnitions of selected economic factors
Economic factors were deﬁned at the center (microeconomic) and
country (macroeconomic) level as follows. Center program duration
was deﬁned by the numbers of years since the ﬁrst transplant. Years
were counted separately for the combination of each main indication
and transplant type (allogeneic versus autologous HSCT) from the ﬁrst
transplant in the center up to the transplant of the individual patients
included in the study (Fig. 1b; supplementary Fig. 1a). Center patient
volume was deﬁned by the number of HSCT by transplant type for
each main indication in the respective year of each of the transplants
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having obtained JACIE accreditation (www.jacie.org) by2012at the latest.
The year 2012 was chosen on purpose; it corresponds to the previous
analysis (Gratwohl et al. 2014).
For the analysis of country-speciﬁc macroeconomic factors, each
country constituted one observation in the data set. As covariates, we
used its HDI (Human Development Index), GNI/cap, Health CareFig. 1.Distribution of center programduration andpatient volume. Theﬁgure depicts the divers
in patient volume according tomain disease indication for the 102,549 patients with an allogene
in Europe between 1999 and 2006. a. Program duration. The graph shows the number of tea
autologous HSCT (right part, green) by the year of ﬁrst transplant from 1970 to 2006. b. Dise
treatment modality (allogeneic HSCT, blue; autologous HSCT, green) and a selected main indi
their respective transplant team. Note that program duration for allogeneic HSCT was longer
acute leukemia were higher than numbers of autologous HSCT. For other main disease indicat
patients (frequency) according to treatmentmodality (allogeneic HSCT, blue; autologousHSCT,
by their respective transplant team in their respective transplant year. Note that the number of
transplanted with an autologous HSCT for this indication; that fewer centers performed allogen
cations, see supplementary Fig. 1.expenditures/capita (HCE/cap), team density (deﬁned as number of
transplant teams per 10 million inhabitants) and transplant rates
(deﬁned as number of transplants per 10 million inhabitants). Informa-
tion on population data and GNI/cap and HCE/cap were obtained from
theWorld Bank (www.worldbank.org). Information onHDIwas obtained
from the United Nations Human Development Report (http://hdr.undp.
org/en/statistics/hdi).ity of the patient population and the heterogeneity in center programduration in years and
ic (N=37,542; 37%) or autologous (N=65,007; 63%) hematopoietic stem cell transplant
ms (frequency) beginning their program to perform allogeneic HSCT (left part, blue) or
ase speciﬁc program duration. The graph illustrates numbers of patients (frequency) by
cation (acute leukemia) according to the program duration in years for this indication of
than for autologous HSCT, as illustrated above in Fig. 1a; Numbers of allogeneic HSCT for
ions, see supplementary Fig. 1. c. Center patient volume. The graph depicts the number of
green) andmain indication (lymphoma) by the number of patients treated for this disease
patients transplanted with an allogeneic HSCT is much lower than the number of patients
eic HSCT for this indication and with lower patient numbers. For other main disease indi-
Fig. 1 (continued).
2104 A. Gratwohl et al. / EBioMedicine 2 (2015) 2101–21092.4. Statistical analysis
The focus of the statistical approach was the interaction between
center- and country-speciﬁc macroeconomic factors, and their possible
effects on outcome. All analyses were adjusted for the established key
risk factors related to patient, disease, donor and transplant technique
(Gratwohl et al. 2009). Covariates in all models were main disease
(acute leukemia, chronic leukemia, myelodysplastic−/myeloprolifera-
tive syndrome, lymphoma and plasma cell disorders) and conditioning
(reduced intensity conditioning/standard conditioning) as stratum.
Included were age in four categories (b20 years, 20–40 years, 40–
60 years and N60 years) and donor relationship for allogeneic HSCT
(HLA-id sibling donor, matched unrelated donor, mismatched related
and unrelated donor) as independent factors. EBMT risk score and calen-
dar year were used as continuous variables. “Center” was included in all
analyses as cluster. Patient volume and program duration were included
as continuous variables.
Survival over an 8 year periodwasmodeled using the center-speciﬁc
factors (program duration, patient volume, and accreditation status) as
well as established treatment, disease, patient and donor risks factors.
An extended COX proportional hazardsmodel was used. For an analysis
at the country level, hazards between countries were analyzed together
with country-speciﬁc macroeconomic factors and searched for a
relation with transplant outcome. Country-speciﬁc hazard ratios were
adjusted for established treatment, disease, patient and donor risks fac-
tors and for patient volume, program duration and center accreditation.
The dependent variable for each country (the variable to be tested for
association with the country-speciﬁc macroeconomic factors) is the
Hazard Ratio of that country in a model containing all patient- and
center-speciﬁc covariates. The hazard ratios for each country are
the country-speciﬁc properties quantifying the excess risk or beneﬁt
for the four endpoints, in each country compared to the average risk
among all countries. Ordinary least squares regressions as well as
parametric and non-parametric correlation coefﬁcients were used
for associations between country-speciﬁc macroeconomic factors
and the country-speciﬁc hazard ratios, again for all four outcome
endpoints.
Country-speciﬁc macroeconomic factors varied over time but with
minor changes in the ranking of the individual countries over time.Regression analyses conﬁrmed the close association of the 2012 value
with the mean value over time (HDI: R2 = 0·967; GNI/cap: R2 =
0·966; HCE/cap: R2 = 0·977; population: R2 = 0·998; supplementary
Fig. 2).We decided therefore to use the year 2012 for data presentation,
for comparability reasons with the selection of the year 2012 as cut off
for accreditation.
3. Results
At the time of the analysis, 61,645 patients were alive, 40,904 had
died. The probability of overall survival at 8 years was 48%, of relapse
free survival 36%, of relapse incidence 45% and of non-relapsemortality
19%. Of note, overall survival declined from 76% at 1 year to 63% at 3
years, and 56% at ﬁve years. Outcome differed signiﬁcantly between
allogeneic and autologous HSCT with higher non-relapse mortality
(30% vs 13%) and lower relapse incidence (33% vs 53%) after allogeneic
HSCT (overall survival 43% vs 51%; relapse free survival 37% vs 35%).
Overall survival improved signiﬁcantly over time for allogeneic HSCT
(per 10 years HR 0·70; 0·64–0.77; p b 0·001) and autologous HSCT
(per 10 years HR 0·69; 0·63–0·76; p b 0·001).
Survival was signiﬁcantly inﬂuenced by EBMT risk score. Overall
survival decreased for each score point (allogeneic HSCT HR 1·21;
1·19–1·23; p b 0·001; autologous HSCT HR 1·17; 1·15–1·19; p b
0·001) due to increasing relapse incidence (allogeneic p b 0·001; autol-
ogous p b 0·001) and non-relapse mortality (allogeneic p b 0·001;
autologous p b 0·001) (Tables 2 and 3).
3.1. Center and country-speciﬁc economic factors
We observed a close interaction between center and country speciﬁc
economic factors but with distinct differences between allogeneic and
autologous HSCT. Centers in higher income countries were more likely
to be accredited (allogeneic HSCT−.678; p b 0.000; autologous HSCT−
.693; p b 0.000) and to have a longer disease speciﬁc experience (alloge-
neic HSCT−.886; p b 0.000; autologousHSCT−.577; p=0.001). Centers
in higher income countries weremore likely to have a higher patient vol-
ume of allogeneic (−.678; p b 0.000) but not of autologous HSCT (−.138;
p = 0.482) (Spearman's rank test, factor vs GNI/cap/HDI).
Table 2
Allogeneic HSCT.
Probability of overall survival (OS), relapse free survival (RFS), relapse incidence (RI), and non-relapse mortality (NRM) after HSCT depending on center speciﬁc economic factors.
Numbers represent hazard ratios (HR), adjusted for all other risk factors by stratiﬁcation (see Methods section for details).
OS RFS RI NRM
Accreditation
JACIE− 1 1 1 1
JACIE+ 0·93 [0.87–0.99] 0·95 [0.90–1.00] 1·00 [0.93–1·06] 0·91 [0·83–0·99]
Center patient volume
Per 10 patients 0·87 [0·84–0·91] 0·92 [0·88–0·96] 0·98 [0·92–1·04] 0·86 [0·82–0·91]
0–4 patients 1 1 1 1
5–9 patients 0·90 0·93 0·96 0·90
10–14 patients 0·86 0·91 0·94 0·88
15–19 patients 0·84 0·90 0·97 0·84
N20 patients 0·78 0·86 0·95 0·76
Center program duration
Per 10 years 0·90 [0·85–0·90] 0·92 [0·87–0·96] 0·93 [0·88–0·99] 0·90 [0·83–0·97]
0–4 years 0·91 0·93 0·88 0·97
5–9 years 0·87 0·89 0·88 0·90
10–14 years 0·84 0·86 0·82 0·90
15–19 years 0·81 0·83 0·85 0·81
EBMT risk score
Per score point 1·21 [1·19–1·23] 1·18 [1·16–1·20] 1·16 [1·14–1·19] 1·20 [1·17–1·22]
Multiplier of the hazard ratio (interaction term in model) for the difference in speed of improvement between accredited and non-accredited centers.
EBMT risk score (score points 0–7 for allogeneic, 0–5 for autologous HSCT: age of patient: b20 years=0, 20–40 years=1, N40=2; disease stage: early= 0, intermediate=1, advanced=2;
time interval fromdiagnosis to transplant: b1 year=0, N1 year=1; allogeneic HSCT only: donor type: HLA id sibling=0; other donor=1; donor recipient gender combination: all other=0,
female donor for male recipient = 1).
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Overall survival was signiﬁcantly higher in JACIE accredited centers
(N = 119 vs 180; HR 0·93; 0·87–0·99; p = 0·03) for patients
transplanted with an allogeneic HSCT due to decreased non-relapse
mortality (Table 2). Results conﬁrmed previous ﬁndings with a now
substantially longer follow up of a minimum of 8 years. We found no
signiﬁcant effects of JACIE accreditation after autologous HSCT (Table 3).
We showed a systematic and signiﬁcant increase in overall and re-
lapse free survival and a systematic decrease in non-relapse mortalityTable 3
Autologous HSCT.
Probability of overall survival (OS), relapse free survival (RFS), relapse incidence (RI), and non
Numbers represent hazard ratios (HR), adjusted for all other risk factors by stratiﬁcation (see M
OS RFS
Accreditation
JACIE− 1 1
JACIE+ 1·08 [1·00–1·15] 1·04 [0·
Center patient volume
Per 10 patients 0·91 [0·87–0·96] 0·93 [0·
0–4 patients 1 1
5–9 patients 0·96 0·96
10–14 patients 0·97 0·95
15–19 patients 0·94 0·93
N20 patients 0·84 0·87
Center program duration
Per 10 years 0·93 [0·87–0·99] 0·92 [0·
0–4 years 1 1
5–9 years 0·98 0·93
10–14 years 0·97 0·91
15–19 years 0·91 0·80
EBMT risk score
Per score point 1·17 [1·15–1·19] 1·14 [1·
Multiplier of the hazard ratio (interaction term in model) for the difference in speed of improv
EBMT risk score (score points 0–7 for allogeneic, 0–5 for autologous HSCT: age of patient: b20 year
time interval fromdiagnosis to transplant: b1 year=0, N1 year=1; allogeneic HSCT only: donor t
female donor for male recipient = 1).and relapse incidence with patient volume, with a decrease in the haz-
ard ratio, quantiﬁed by steps of 10 patients (HR 0·87; 0·84–0·91;
p b 0·001 for overall survival in allogeneic HSCT (Fig. 2a); HR 0·91;
0·87–0·96; p b 0·001 in autologous HSCT) (Tables 2 and 3). The same
systematic and signiﬁcant increases in overall and relapse free survival
were observed with increasing disease-speciﬁc center program dura-
tion, quantiﬁed in steps of 10 years (HR 0·90; 0·85–0·90; p b 0·001
for overall survival in allogeneic (Fig. 2b); HR 0·93; 0·87–0·99;
p b 0·02 in autologous HSCT). Signiﬁcant effects were seen on both-relapse mortality (NRM) after HSCT depending on center speciﬁc economic factors.
ethods section for details).
RI NRM
1 1
99–1·11] 1·07 [0·99–1·17] 0·93 [0·80–1·07]
89–0·97] 0·92 [0·87–0·98] 0·96 [0·87–1·07]
1 1
0·96 0·93
0·95 0·97
0·94 0·90
0·86 0·92
87–0·98] 0·92 [0·84–0·98] 0·99 [0·88–1·11]
1 1
0·92 0·96
0·89 0·99
0·88 0·95
12–1·16] 1·10 [1·08–1·13] 1·30 [1·26–1·34]
ement between accredited and non-accredited centers.
s= 0, 20–40 years=1, N40=2; disease stage: early= 0, intermediate=1, advanced=2;
ype: HLA id sibling=0; other donor=1; donor recipient gender combination: all other=0,
Fig. 2. Center speciﬁc microeconomic aspects and overall survival. The graphs illustrate
Cox model estimates of overall survival of 37,542 patients with an allogeneic HSCT by
center speciﬁc microeconomic aspects (for deﬁnitions see Methods section). The model
integrates year of transplant, years of experience, size of the center, main disease indica-
tion, EBMT risk score, conditioning and accreditation status as factors. a. Patient volume.
The graph shows Cox model estimates of overall survival depending on patient volume
in absolute numbers. Numbers give numbers of patients treated for the respective disease
in the year of the transplant at the patients' center (0–4 patients blue, 5–9 patients green,
10–14 patients yellow, 15–19 patients purple, 20 patients and N20 patients red). b. Pro-
gram duration. The graph shows Cox model estimates of overall survival depending on
the centers program duration in years for. Numbers give numbers of years of program
duration at the time of the transplant (0–4 years blue, 5–9 years green, 10–14 years yellow,
15–19 years purple, 20 years and N20 years red).
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on relapse incidence after autologous HSCT (Tables 2 and 3).
3.2. Country-speciﬁc macroeconomic factors and outcome
Integrating these center speciﬁc microeconomic factors at the indi-
vidual patient level, outcome over the 8 year period of observation
differed signiﬁcantly between individual countries, independent of,
but adjusted for patient, donor, and disease and center-speciﬁc risk
factors. The effects differed for the individual macroeconomic factorsby type of HSCT and the endpoint assessed. After allogeneic HSCT, over-
all survival and relapse free survival were signiﬁcantly higher, and non-
relapse mortality and relapse incidence lower in countries with higher
economic indices. Relapse free survival, was signiﬁcantly associated
with GNI/cap (R2 16%; p = 0·009), HDI (R2 21%; p = 0·012), HCE/cap
(R2 20%; p = 0·016) or higher transplant rates (R2 16%; p = 0·017)
in univariate analysis. All macroeconomic factors were closely related
with each other; in multivariate analysis, the product of HCE by GNI/
cap (R2 = 18%; p = 0·004) (Fig. 3a) remained the sole signiﬁcant var-
iable. In contrast, no signiﬁcant associations between country-speciﬁc
macroeconomic factors and outcome could be found after autologous
HSCT (Fig. 3b).
Of interest, there was no signiﬁcant correlation between the hazard
ratios of the individual countries for allogeneic and autologous HSCT,
with one exception. Countries with lower levels of non-relapse mor-
tality after allogeneic HSCT had a lower non-relapse mortality after
autologous HSCT as well (R2 = 25%; p = 0·011).4. Discussion
Country- and center-speciﬁc economic factors were signiﬁcantly as-
sociatedwith outcome in this large cohort of patients treatedwith an al-
logeneic or autologous HSCT. Survivalwas signiﬁcantly and consistently
better when the transplant was performed in a center with a higher pa-
tient volume andwith longer programduration. It was signiﬁcantly bet-
ter after allogeneic HSCT when the transplant was performed in an
accredited team and in a country with more resources. The effects on
outcomewere systematic and clinically relevant but therewere distinct
differences between allogeneic and autologous HSCT. The observed
better overall and relapse free survival after allogeneic HSCT was ac-
companied by a similar systematic reduction in relapse incidence and
non-relapse mortality. In contrast, improved survival after autologous
HSCT with increasing patient volume or program duration was restrict-
ed to a systematic reduction in relapse incidence; there were no signif-
icant associations with non-relapse mortality, with accreditation or
with country speciﬁc macroeconomic factors.
These differences between allogeneic and autologous HSCT warrant
some explanations, as the systematic pattern of the effects renders a
simple chance ﬁnding unlikely. They help as well to understand the
ﬁndings. Allogeneic HSCT is a highly complex procedure with non-
relapse mortality as the main cause of failure, autologous HSCT is less
complex but with a high risk of relapse (Copelan 2006; Gratwohl et al.
2009). HSCT is not an isolated procedure; outcome depends on the
pre-transplant history, the patient and donor selection and includes
long-term post-transplant follow-up. Only half of the mortality occurs
within the ﬁrst year after HSCT. Success requires expertise in disease
and complication management and the close collaboration of multiple
individuals at various levels and over a long time period. Longer pro-
gram duration and a higher patient volume can improve expertise in
disease management, as shown by the reduced relapse rate and im-
proved survival for all patients. Longer program duration, a higher pa-
tient volume and standardized patient management (indicated by the
JACIE accreditation) can improve expertise in complication manage-
ment as shown by the reduced non-relapse mortality after the more
complex allogeneic HSCTwith its inherently higher non-relapsemortal-
ity. These microeconomic center effect ﬁndings ﬁt with the macroeco-
nomic country observations. The impact of more resources for the
health care system in a given country (indicated by the proportion of
HCE/cap of the respective GNI/cap) and of the network infrastructure
(as indicated by theHDI) becamevisible only after themore complex al-
logeneicHSCTwith its higher non-relapsemortality over a long timepe-
riod. More resources are required to achieve sufﬁcient expertise for the
team, and to maintain the pre- and post-transplant networks for indi-
vidual patients (Majhail et al. 2012). This is probably best reﬂected by
the lower long-term survival of patients transplanted in the years
Fig. 3. Country speciﬁc macroeconomic aspects and overall survival: impact of total Health Care Expenditures as a fraction of GNI/cap. The graphs depict the regression analyses of the
country speciﬁc risk of death (inverse of overall survival) after HSCT against the respective countries Health Care Expenditures as a fraction of its GNI/cap. Country speciﬁc hazard ratios
were adjusted for established treatment, disease, patient and donor risks factors as well as for center size, center experience and center accreditation (for details see Methods section).
3a. Allogeneic HSCT. The graph depicts the regression analysis of country speciﬁc hazards after allogeneic HSCT against the Health Care Expenditures as a fraction of GNI/cap. Spearman
rank test: R2 = 0·21; p= 0·01. Abbreviations correspond to the respective country codes. b. Autologous HSCT. The graph depicts the regression analysis of country speciﬁc hazards after
autologous HSCT against the Health Care Expenditures as a fraction of GNI/cap. Spearman R2 = 0·03 (3% explained variance); p = 0·38. Abbreviations correspond to the respective
country codes.
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2012.
The present ﬁndings ﬁt into ongoing general discussions on quality
assurance, safety issues, center comparisons and minimum numbers
of patients required for speciﬁc complex treatments (Horowitz et al.
1992; Taylor et al. 2013; Hunsicker et al. 1993; Ozhathil et al. 2011;
Guba 2014; Birkmeyer et al. 2003; Lüchtenborg et al. 2013). Our data in-
dicate that there is no threshold, rather a systematic impact of both, ex-
perience in years and experience in numbers. “Center effects” therefore
should not be reduced to just one aspect, such as patient volume, learn-
ing curve or surgical skills (Guba 2014; Birkmeyer et al. 2003). Micro-
economic center-speciﬁc effects comprise program duration, patient
volume, center accreditation as well as training programs, standardiza-
tion and individual skills; they are complemented by the respective
country-speciﬁc factors. Data show as well that team expertise in dis-
ease and complication management is required for optimal outcome
(Majhail et al. 2012).Measuring day 30 or day 100 mortality alone is
an insufﬁcient measure of quality assurance when long-term disease
free survival presents the most valid endpoint. As evidenced by this
study, individual center- or country-speciﬁc economic factors may
impact variably according to and depending on the complexity of the
procedure (Greenﬁeld et al. 2014; Apperley et al. 2000). Our results
potentially apply to solid organ transplantation and other ﬁelds of com-
plex medical care as well.
Our study has some limitations.We describe associations, not causal
effects. A higher patient volume may not necessarily improve survival
and a long-established institution still can have poor results. We tried
to adjust for key patient-, donor- and treatment-related factors. We
cannot exclude that patient risk proﬁles differed signiﬁcantly between
centers or countries and might have accounted for some of the differ-
ences. We have no explanation why the country speciﬁc hazards were
favorable in some after allogeneic but not autologous, or vice versa or
after both. Further studies are required, not to address “who is better”,
but rather to dissect potential reasons for the differences, and what
measures are required to improve clinical practice, education, compe-
tency and infrastructure in centers with poorer outcomes to make
them as good as those centers with the best outcomes. We could not
identify signiﬁcant associations of economic factors with non-relapse
mortality after autologous HSCT. The relative low non-relapsemortality
is an insufﬁcient explanation per se;we observed a signiﬁcant reduction
of non-relapse mortality over time and found a positive correlation in
country speciﬁc non-relapse mortality for autologous and allogeneic
HSCT. The larger, accredited teams showed a trend for lower non-
relapse mortality but higher relapse incidence; they might have a
shorter waiting time, associated with a slightly higher risk proﬁle
of their patients (Frassoni et al. 2000).
The results of this report have implications. Outcome comparisons
directed to patients will need to integrate country- and center-speciﬁc
micro- and macroeconomic factors for an informative evaluation of
the disease-speciﬁc experience of their respective transplant center.
Transplant organizations and transplant centers will have to consider
concentration on speciﬁc disease entities. The prospect of every trans-
plant team embarking on or continuing HSCT for all potential indica-
tions should be reappraised by transplant communities and health
service commissioners, and concentration of clinical practice may
improve outcomes in a deﬁned population or region. Those looking to
establish new centers should embark on transplant activity if they
have sufﬁcient resources for infrastructure and a clear perspective
to achieve adequate activity and accreditation over a rapid and pre-
deﬁned time period. Professional organizations such as EBMT and
JACIE are challenged to support emerging teams in less privileged coun-
tries via training and partnership programs to achieve these goals. Small
centers in high income countries and close to existing larger enters, in
contrast, might need to reconsider their activities. Competent authorities
should be aware of these results which might not be restricted to HSCT.
They should foster, in cooperation with the transplant organizations,regulations and legislations, and facilitate regional task distribution
(Jones et al. 2006).
In conclusion, these results show that macroeconomic factors are
systematically and signiﬁcantly associated with outcome after HSCT.
Clinical HSCT practice should accommodate for the needs of individual
patients with speciﬁc disease states, with the appropriate stem cell pro-
cedure, delivered at experienced transplant centers, thereby providing
better outcomes regarding long-term survival, quality of life and cost-
effectiveness, compared to any other non-transplant strategy. We rec-
ommend that micro- and macroeconomic factors should be integrated
into clinical transplant practice for both, individual patients and for
the cooperative working between regional transplant centers, to im-
prove outcomes through better patient selection and increased exper-
tise in disease- and complication management.Funding
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